Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iodine-125 particle implantation plus nimotuzumab and chemotherapy for unresectable pancreatic cancer
ChiCTR2500111167Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nimotuzumab in pancreatic adenocarcinoma (PDAC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Progression-free survival. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2500111167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111167.